Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2012

Open Access 01-12-2012 | Research

Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer

Authors: Xing Hua, Lina Yu, Wenhai Pan, Xiaoxiao Huang, Zexiao Liao, Qi Xian, Li Fang, Hong Shen

Published in: Diagnostic Pathology | Issue 1/2012

Login to get access

Abstract

Background

To investigate the expression of Golgi phosphoprotein-3 (GOLPH3) in prostate cancer and determine its prognostic value.

Methods

Immunohistochemical staining for GOLPH3 was performed on tissue microarrays of 342 prostate patients. The correlation between GOLPH3 expression with its clinicopathologic factors was also analyzed in order to determine its prognostic significance.

Results

GOLPH3 expression of normal prostate tissues, benign prostate hyperplasia, high-grade prostatic intraepithelial neoplasia, and hormone-dependent prostate cancer (HDPC) did not show any statistically significant difference. In contrast, statistically significant difference was reported in moderate/intense GOLPH3 expression in cases diagnosed with HDPC and castration resistant prostate cancer (CRPC) (P < 0.0005). Moderate /intense expression of GOLPH3 was associated with androgen independence (P = 0.012), higher Gleason score (P = 0.017), bone metastasis (P = 0.024), higher baseline prostate-specific antigen (PSA) (P = 0.038), and higher PSA nadir (P = 0.032). A significantly negative correlation was found between moderate/intense GOLPH3 expression and disease-free survival (DFS) (HR = 0.28, P = 0.012) and overall survival (OS) (HR = 0.42, P = 0.027). Univariated analysis indicated that moderate/intense GOLPH3 expression created a significantly prognostic impact in patients with CRPC. On the other hand, multivariate analysis indicated that GOLPH3 was a significantly independent prognostic factor of DFS (P = 0.027) in all prostate cancer patients.

Conclusions

In this study, it was discovered that the overexpression of GOLPH3 is associated with the transition of prostate cancer from hormone sensitive phase to hormone refractory phase. GOLPH3 might be an important prognostic factor of DFS and OS in patients with prostate cancer. In totality, GOLPH3 could be used as a novel candidate in devising a more effective therapeutic strategy to tackle CRPC.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​1452541171722856​.
Appendix
Available only for authorised users
Literature
1.
Niu Z, Guohua R, Shuping S: Diagnosis and treatment for prostate cancer. Chinese–German. J Clin Oncol. 2008, 7: 492-494.
2.
Debes JD, Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004, 351: 1488-1490. 10.1056/NEJMp048178.CrossRefPubMed
3.
Fritzsche FR, Stephan C, Gerhardt J, Lein M, Hofmann I, Jung K, Dietel M, Kristiansen G: Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer. Histol Histopathol. 2010, 25: 733-739.PubMed
4.
Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson LM: Biomarkers for prostate cancer detection. J Urol. 2007, 178: 2252-2259. 10.1016/j.juro.2007.08.055.CrossRefPubMed
5.
Dippold HC, Ng MM, Farber-Katz SE: GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell. 2009, 139: 337-351. 10.1016/j.cell.2009.07.052.PubMedCentralCrossRefPubMed
6.
Wood CS, Schmitz KR, Bessman NJ: PtdIns4P recognition by Vps74/GOLPH3 links PtdIns 4-kinase signaling to retrograde Golgi trafficking. J Cell Biol. 2009, 187: 967-975. 10.1083/jcb.200909063.PubMedCentralCrossRefPubMed
7.
Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhaka S, Wu M, Chen SJ, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao YH, Rimm DL, Protopopov A, Wong KK, Chin L: GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature. 2009, 459: 1085-1090. 10.1038/nature08109.PubMedCentralCrossRefPubMed
8.
Abraham RT: GOLPH3 links the Golgi network to mTOR signaling and human cancer. Pigment Cell Melanoma Res. 2009, 22: 378-379. 10.1111/j.1755-148X.2009.00596.x.CrossRefPubMed
9.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallionimeni OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4: 844-847. 10.1038/nm0798-844.CrossRefPubMed
10.
He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T: Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012, 29: 406-410. 10.1007/s12032-011-9832-0.CrossRefPubMed
11.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 2006, 56: 106-130. 10.3322/canjclin.56.2.106.CrossRefPubMed
12.
13.
de la Fouchardière C, Flechon A, Droz JP: Coagulopathy in prostate cancer. Neth J Med. 2003, 61: 347-354.PubMed
14.
Wedel S, Hudak L, Seibel J-M, Makarevic J, Juengel E, Tsaur I, Waaga-Gasser A, Haferkamp A, Blaheta RA: Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer. 2011, 11: 375-10.1186/1471-2407-11-375.PubMedCentralCrossRefPubMed
15.
Moussa AS, Li J, Soriano M, Klein EA, Dong F, Jones JS: Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int. 2009, 103: 43-48. 10.1111/j.1464-410X.2008.08059.x.CrossRefPubMed
16.
Denham JW, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, Duchesne G, Ebert M, Steigler A, Este CD: PSA response signatures – a powerful new prognostic indicator after radiation for prostate cancer?. Radiother Oncol. 2009, 90: 382-388. 10.1016/j.radonc.2008.10.004.CrossRefPubMed
17.
Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, Amico AVD: Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer. Clin Cancer Res. 2004, 10: 3927-3933. 10.1158/1078-0432.CCR-03-0788.CrossRefPubMed
18.
Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute M: Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: Impact on prostate cancer specific survival. J Urol. 2006, 175: 547-551. 10.1016/S0022-5347(05)00152-7.CrossRefPubMed
19.
Helpap B, Egevad L: Modified Gleason grading. An updated review. Histol Histopathol. 2009, 24: 661-666.PubMed
20.
Hara N, Kitamura Y, Saito T, Komatsubara S: Total and free prostate-specific antigen indexes in prostate cancer screening: value and limitation for Japanese populations. Asian J Androl. 2006, 8: 429-434. 10.1111/j.1745-7262.2006.00155.x.CrossRefPubMed
21.
Bin W, He W, Feng Z, Xiangdong L, Yong C, Lete K, Hongbin Z, Honglin G: Prognostic relevance of cyclooxygenase-2 (COX-2) expression in Chinese patients with prostate cancer. Acta Histochem. 2011, 113: 131-136. 10.1016/j.acthis.2009.09.004.CrossRefPubMed
22.
Isaacs JT, Wake N, Coffey DS, Sandberg AA: Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res. 1982, 42: 2353-2371.PubMed
23.
Miyake H, Tolcher A, Gleave ME: Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgenindependence after castration in the Shionogi tumor model. Cancer Res. 1999, 59: 4030-4034.PubMed
24.
Miyake H, Nelson C, Rennie PS, Gleave ME: Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 2000, 60: 170-176.PubMed
25.
Miyake H, Pollak M, Gleave ME: Castration-induced upregulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen-independence in prostate cancer models. Cancer Res. 2000, 60: 3058-3064.PubMed
26.
Bubulya A, Wise SC, Shen XQ, Burmeister LA, Shemshedini L: c-Jun can mediate androgen receptorinduced transactivation. J Biol Chem. 1996, 271: 24583-24589. 10.1074/jbc.271.40.24583.CrossRefPubMed
27.
Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME: Androgenic induction of prostate-specific antigen gene is repressed by protein–protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem. 1997, 272: 17485-17494. 10.1074/jbc.272.28.17485.CrossRefPubMed
28.
Craft N, Shostak Y, Carey M, Sawyers CL: A mechanism for hormone-independent prostate cancerthrough modulation of androgen receptor signalingby the HER–2/neu tyrosine kinase. Nat Med. 1999, 5: 280-285. 10.1038/6495.CrossRefPubMed
29.
Fingar DC, Salama S, Tsou C, Harlow E, Blenis J: Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002, 16: 1472-1487. 10.1101/gad.995802.PubMedCentralCrossRefPubMed
30.
Feng Z, Zhang H, Levine AJ, Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA. 2005, 102: 8204-8209. 10.1073/pnas.0502857102.PubMedCentralCrossRefPubMed
31.
Jacinto E, Hall MN: Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol. 2003, 4: 117-126. 10.1038/nrm1018.CrossRefPubMed
32.
Oldham S, Hafen E: Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol. 2003, 13: 79-85. 10.1016/S0962-8924(02)00042-9.CrossRefPubMed
33.
Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell. 2000, 103: 253-262. 10.1016/S0092-8674(00)00117-3.CrossRefPubMed
Metadata
Title
Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer
Authors
Xing Hua
Lina Yu
Wenhai Pan
Xiaoxiao Huang
Zexiao Liao
Qi Xian
Li Fang
Hong Shen
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2012
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-7-127

Other articles of this Issue 1/2012

Diagnostic Pathology 1/2012 Go to the issue

Research

Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors

Case Report

Malignant transformation of Madelung’s disease in a patient with a coincidental diagnosis of breast cancer: a case report

Research

Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study

Research

Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens

Case Report

Primary mesenchymal chondrosarcoma of the kidney with synchronous implant and infiltrating urothelial carcinoma of the ureter

Case Report

Renal infarction due to polyarteritis nodosa in a patient with angioimmunoblastic T-cell lymphoma: a case report and a brief review of the literature